secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apimeds Pharmaceuticals US, Inc. (APUS)
CIK:        0001894525
Form:       8-K
Filed at:   2025-11-18T23:59:59+00:00
Accession:  0001213900-25-112184
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apimeds boosts CEO salary to $500K and adds 24-month severance with equity vesting
--------------------------------------------------------------------------------

- CEO Erik Emerson's annual base salary increased to $500,000, effective Nov 13, 2025.
- If terminated without cause, Emerson gets 24 months salary/benefits plus immediate vesting of all unvested equity.
- On termination for cause or voluntary quit without good reason, unvested equity forfeited automatically.
- Amendment modifies the original Sept 21, 2023 employment agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894525/000121390025112184/0001213900-25-112184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894525/000121390025112184/ea0266166-8k_apimeds.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-112184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer